阿片类药物使用障碍患者的痛觉过敏:系统综述与Meta分析
该系统综述与Meta分析纳入39项研究(1385例患者、741例对照),评估有阿片类药物使用障碍(OUD)史者在冷压痛测试中的痛反应。接受阿片受体激动剂治疗的患者较对照痛阈平均低2至3秒、耐痛时间低29秒;Meta回归未明确支持痛觉过敏与阿片使用相关。
要点
- 接受阿片受体激动剂治疗的OUD患者较健康对照对冷痛更敏感,痛阈和耐痛时间均降低。
- Egger检验提示上述差异可能被高估,且部分研究存在样本匹配不足和受试者脱落偏倚。
- Meta回归未明确支持痛觉过敏与阿片使用相关,其发生顺序和因果关系仍不明确。
核心结论
- 接受阿片受体激动剂治疗的OUD患者对冷痛过敏,但痛觉过敏是发生于长期阿片治疗之前、独立于还是源于长期阿片治疗仍不清楚。
- 作者建议未来研究应探讨痛觉过敏对患者健康状态和治疗结局的影响。
研究设计与样本
- 系统综述与Meta分析,检索Web of Science、PubMed和Embase(2023年3月1日至2024年4月12日)。
- 纳入评估有OUD史者在寻求治疗、药物治疗或戒断期间冷压痛测试痛反应的研究,共39项研究(1385例患者、741例对照)。
- 采用多水平随机效应模型与稳健方差估计分析,研究质量用JBI清单评价,漏斗图和Egger回归检验评估报告偏倚。
主要发现
- 多数研究报告接受阿片受体激动剂治疗患者的冷压痛测试数据,其痛阈较对照平均低2至3秒(95%CI -4至-1;t检验P=0.01;百分比差异-22%;Hedges g=-0.5)。
- 接受阿片受体激动剂治疗患者的耐痛时间较对照平均低29秒(95%CI -39至-18;t检验P<0.001;百分比差异-52%;Hedges g=-0.9)。
- Egger检验提示上述差异可能被高估,部分研究存在样本匹配不足和受试者脱落导致的偏倚担忧。
- Meta回归未明确支持痛觉过敏与阿片使用相关。
关键数值与推荐
- 痛阈差异:接受阿片受体激动剂治疗患者较对照平均低2至3秒(95%CI -4至-1;t检验P=0.01;百分比差异-22%;Hedges g=-0.5)。
- 耐痛时间差异:接受阿片受体激动剂治疗患者较对照平均低29秒(95%CI -39至-18;t检验P<0.001;百分比差异-52%;Hedges g=-0.9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- Egger检验提示痛阈和耐痛时间的差异可能被高估。
- 部分研究存在样本匹配不足和受试者脱落导致的偏倚担忧。
- Meta回归未明确支持痛觉过敏与阿片使用相关,痛觉过敏发生于长期阿片治疗之前、独立于还是源于长期阿片治疗仍不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Short-term and long-term opioid treatment have been associated with increased pain sensitivity (ie, opioid-induced hyperalgesia). Treatment of opioid use disorder (OUD) mainly involves maintenance with methadone and buprenorphine, and observations of heightened cold pain sensitivity among patients are often considered evidence of opioid-induced hyperalgesia. OBJECTIVE: To critically examine the evidence that hyperalgesia in patients with OUD is related to opioid use. DATA SOURCES: Web of Science, PubMed, and Embase between March 1, 2023, and April 12, 2024, were searched. STUDY SELECTION: Studies assessing cold pressor test (CPT) pain responses during treatment seeking, pharmacological treatment, or abstinence in patients with OUD history were included. DATA EXTRACTION AND SYNTHESIS: Multilevel random-effects models with robust variance estimation were used for all analyses. Study quality was rated with the JBI checklist. Funnel plots and Egger regression tests were used to assess reporting bias. MAIN OUTCOMES AND MEASURES: Main outcomes were pain threshold, tolerance, and intensity in patients and healthy controls, and unstandardized, standardized (Hedges g), and percentage differences (%Δ) in these measures between patients and controls. The association between pain sensitivity and opioid tolerance, withdrawal, and abstinence indices was tested with meta-regression. RESULTS: Thirty-nine studies (1385 patients, 741 controls) met the inclusion criteria. Most studies reported CPT data on patients undergoing opioid agonist treatment. These patients had a mean 2- to 3-seconds lower pain threshold (95% CI, -4 to -1; t test P = .01; %Δ, -22%; g = -0.5) and 29-seconds lower pain tolerance (95% CI, -39 to -18; t test P < .001; %Δ, -52%; g = -0.9) than controls. Egger tests suggested that these differences may be overestimated. There were some concerns of bias due to inadequate sample matching and participant dropout. Meta-regressions yielded no clear support for hyperalgesia being opioid related. CONCLUSION AND RELEVANCE: Patients receiving opioid agonist treatment for OUD are hypersensitive to cold pain. It remains unclear whether hyperalgesia develops prior to, independent of, or as a result of long-term opioid treatment. Regardless, future studies should investigate the impact of hyperalgesia on patients' well-being and treatment outcomes.
引用
- Trøstheim M, Eikemo M. Hyperalgesia in Patients With a History of Opioid Use Disorder: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024. PMID: 39141367. doi:10.1001/jamapsychiatry.2024.2176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。